Clinical Trials List
2022-04-01 - 2028-09-30
Phase III
Not yet recruiting7
Recruiting1
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chong-Jen Yu 未分科
- 徐偉勛 無
- James Chih-Hsin Yang 無
- 錢穎群 無
- 黃得瑞 Division of Hematology & Oncology
- 廖唯昱 無
- Chia-Chi Lin 無
- 蔡子修 無
- 黃俊凱 無
- CHAO-CHI HO CHAO-CHI HO 未分科
- 廖斌志 無
- 林昭文 無
- 許嘉林 無
- YEN-TING LIN 無
- 吳尚俊 未分科
- Jih-Hsiang Lee 無
- 楊景堯 無
- 陳冠宇 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
698 participants
